Review anchor
Mitogen-activated protein kinase kinase kinase 20
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
Evidence Snapshot
Mitogen-activated protein kinase kinase kinase 20
CHEMBL3886
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Mitogen-activated protein kinase kinase kinase 20 as ChEMBL target CHEMBL3886, mapped to UniProt Q9NYL2. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL3886
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q9NYL2
Mitogen-activated protein kinase kinase kinase 20
UniProt accession via ChEMBL component mapping
As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-14
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Mitogen-activated protein kinase kinase kinase 20 matters
Mitogen-activated protein kinase kinase kinase 20 is reviewed as Mitogen-activated protein kinase kinase kinase 20 (UniProt Q9NYL2); the current evidence base includes 22 approved drugs, 1379 compounds, and 242 assays, with lead potency reaching pChEMBL 8.7.
Protein context
Mitogen-activated protein kinase kinase kinase 20
Mitogen-activated protein kinase kinase kinase 20 Sequence length is 800 aa.
Review this target as Mitogen-activated protein kinase kinase kinase 20, mapped to UniProt Q9NYL2. Sequence length is 800 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt Q9NYL2
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 22 approved drugs, 1379 compounds, and 242 assays for this target. The dominant activity type is KI. CHEMBL4524151 is the current potency anchor at pChEMBL 8.7.
Use CHEMBL4524151 as the tractability anchor when discussing potency (pChEMBL 8.7).
Activity source · ChEMBL 36 via Core Engine
22 approved
pChEMBL 8.7
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Mitogen-activated protein kinase kinase kinase 20 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q9NYL2, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
1379
Total Compounds
242
Total Assays
22
Approved Drugs
IC50: 122.0, KI: 610.0, EC50: 1.0, KD: 375.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL4524151
|
8.7 | IC50 | — |
|
|
No preferred name
CHEMBL4542865
|
8.7 | IC50 | — |
|
|
No preferred name
CHEMBL4526537
|
8.6 | IC50 | — |
|
|
No preferred name
CHEMBL574738
|
8.6 | Kd | — |
|
|
No preferred name
CHEMBL4098896
|
8.6 | Kd | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
TOVORAFENIB
CHEMBL3348923
|
2024 |
|
|
FEDRATINIB
CHEMBL1287853
|
2019 |
|
|
ENCORAFENIB
CHEMBL3301612
|
2018 |
|
|
DABRAFENIB
CHEMBL2028663
|
2013 |
|
|
PONATINIB
CHEMBL1171837
|
2012 |
|
|
BOSUTINIB
CHEMBL288441
|
2012 |
|
|
REGORAFENIB
CHEMBL1946170
|
2012 |
|
|
VEMURAFENIB
CHEMBL1229517
|
2011 |
|
|
NILOTINIB
CHEMBL255863
|
2007 |
|
|
DASATINIB
CHEMBL5416410
|
2006 |
|
|
DASATINIB ANHYDROUS
CHEMBL1421
|
2006 |
|
|
SORAFENIB
CHEMBL1336
|
2005 |
Source Header